Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
Welf Prager,1 Eva K Bee,2 Isabel Havermann,1 Ina Zschocke3 1Dermatologikum Hamburg, Hamburg, Germany; 2Praxis für Dermatologie, Hautarztpraxis Stengel and Bee, Münster, Germany; 3SCIderm, Hamburg, Germany Background: IncobotulinumtoxinA (Bocouture®) is free from complexing...
Enregistré dans:
Auteurs principaux: | Prager W, Bee EK, Havermann I, Zschocke I |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/932974b03b53414ebb1a1743670cf9a7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
par: Prager W
Publié: (2013) -
Intraoral alveolar submucosal injections of Incobotulinumtoxin A: Relief of therapy-refractory trigeminal neuropathy after tooth extraction
par: Lars Wojtecki, et autres
Publié: (2021) -
Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
par: Stengel G, et autres
Publié: (2011) -
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
par: Park J, et autres
Publié: (2011) -
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
par: Santamato A
Publié: (2016)